| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2020-03-23 | Soligenix (USA - NY) the University of Hawai?i at M?noa (USA) | COVID-19, coronavirus infection | research | Infectious diseases | Research agreement | |
| 2020-02-26 | Gemini Therapeutics (USA) - Singapore Eye Research Institute (SG) | new targets associated with age-related macular degeneration | Age-related Macular Degeneration (AMD), polypoidal choroidal vasculopathy | R&D | Ophthalmological diseases - Cardiovascular diseases | Research agreement |
| 2020-02-12 | Sangamo Therapeutics (USA - CA) | member of the board | nomination | Nomination | ||
| 2019-12-23 | Sangamo Therapeutics (USA - CA) Pfizer (USA - NY) | gene therapy programs for hemophilia A, including SB-525 | hemophilia A | licensing - development - commercialisation | Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2019-11-26 | Sangamo Therapeutics (USA - CA) | member of the board | nomination | Nomination | ||
| 2019-11-08 | Sangamo Therapeutics (USA - CA) | scientific advisory board | nomination | Nomination | ||
| 2019-09-30 | Sangamo Therapeutics (USA - CA) | senior vice president, chief medical officer | nomination | Nomination | ||
| 2019-09-13 | Gemini Therapeutics (USA) | CEO | nomination | Rare diseases - Genetic diseases- Ophthalmological diseases | Nomination | |
| 2019-07-31 | Sangamo Therapeutics (USA - CA) | executive vice president and general counsel | nomination | Nomination | ||
| 2019-06-19 | Genzyme (USA - MA), a Sanofi company (France) Voyager Therapeutics (USA - MA) | gene therapy programs for Parkinson’s disease, Friedreich’s ataxia, Huntington’s disease and other CNS disorders | Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease and other CNS disorders | development - commercialisation | CNS diseases - Neurodegenerative diseases | Development agreement |
| 2019-05-20 | Voyager Therapeutics (USA-MA) | head of R&D | nomination | Neurological diseases - Neurodegenerative diseases | Nomination | |
| 2019-04-02 | Sangamo Therapeutics (USA - CA) Brammer Bio (USA - CA) | large-scale AAV manufacturing | manufacturing - production | Production agreement | ||
| 2019-03-12 | Sangamo Therapeutics (USA - CA) | senior vice president cell therapy | nomination | Nomination | ||
| 2019-02-27 | Sangamo Therapeutics (USA - CA) Biogen (USA - MA) | ST-501, ST-502, and a neuromuscular target | tauopathies including Alzheimer’s disease, synucleinopathies including Parkinson’s disease | licensing - development - commercialisation | Neurological diseases - Neurodegenerative diseases - Neuromuscular diseases | Licensing agreement |
| 2019-02-22 | Voyager Therapeutics (USA-MA) Abbvie (USA - IL) | vectorized antibodies directed at pathological species of alpha-synuclein | Parkinson's disease and diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein | development - commercialisation | Neurological diseases - Neurodegenerative diseases | Development agreement |
| 2019-01-22 | Voyager Therapeutics (USA-MA) | general counsel | nomination | Neurological diseases - Neurodegenerative diseases | Nomination | |
| 2019-01-22 | Voyager Therapeutics (USA-MA) Neurocrine Biosciences (USA - CA) | VY-AADC, VY-FXN01 | Parkinson’s Disease - Friedreich’s Ataxia | development, commercialization | Rare diseases - Neurological diseases - Neurodegenerative diseases | Development agreement |
| 2019-01-15 | Voyager Therapeutics (USA-MA) | chief medical officer | nomination | Neurological diseases - Neurodegenerative diseases | Nomination | |
| 2019-00-22 | Sangamo Therapeutics (USA - CA) | vice president Research & Development (R&D) | nomination | Nomination | ||
| 2018-12-17 | Voyager Therapeutics (USA-MA) The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (USA) | Parkinson’s Disease Education Consortium, Parkinson’s Progression Markers Initiative | Parkinson's disease | collaboration | Neurological diseases - Neurodegenerative diseases | Collaboration agreement |
